Introduction: Myeloid leukemia (ML) is defined as the neoplastic transformation of hematopoietic cells of the myeloid lineage. It can be classified into two main types: chronic, which involves the proliferation of mature cells, and acute, which is characterized by the proliferation of progenitor cells. Acute myeloid leukemia (AML) accounts for 15% to 20% of childhood acute leukemia cases and is responsible for approximately 30% of deaths in this population. Although AML incidence increases with age, the disease has a high complete remission rate in children, reaching approximately 90% of cases. Chronic myeloid leukemia (CML), on the other hand, primarily affects older adults. According to the National Cancer Institute (INCA), between 2020 and 2022, 10,810 new leukemia cases were reported in Brazil, with 15% classified as CML. Objectives: To assess mortality patterns of myeloid leukemia in the Northern Region of Brazil from 2019 to 2023. Methods: This is a descriptive, retrospective epidemiological study on mortality due to myeloid leukemia in the Northern Region of Brazil. Data were extracted from the Mortality Information System (SIM), accessed via the TABNET platform provided by DATASUS. The analysis included the following variables: ICD-10 category C92, geographic region (North), federative unit, year of death, age group, sex, and race/skin color from 2019 to 2023. Results: A total of 924 deaths from myeloid leukemia were recorded in the Northern Region of Brazil between 2019 and 2023, representing a 7% increase compared to the previous five-year period, which reported 859 deaths. The majority of deaths occurred in the states of Pará (42.8%, n=396) and Amazonas (19.2%, n=172), followed by Rondônia (12.8%, n=119), Tocantins (11.4%, n=106), and the states of Acre, Amapá, and Roraima, each with less than 7% of cases. Regarding sex distribution, males accounted for 55.4% (n=511) of deaths. In terms of race/skin color, 66.3% (n=612) of individuals were brown, 24.8% (n=229) white, 4.4% (n=40) Black, 1.1% (n=10) Indigenous, and 0.5% (n=4) Asian, reflecting the region’s predominant ethnic profile. Patient age ranged from 1 year to over 80, with the highest prevalence among individuals aged 60–69 and 70–79, representing 32.4% (n=299) of deaths. Conclusion: From 2019 to 2023, the Northern Region of Brazil experienced a 7% increase in myeloid leukemia mortality, totaling 924 deaths. Most occurred in the states of Pará and Amazonas, likely due to their larger populations and greater capacity for diagnosis and reporting. Deaths were more frequent among men, brown-skinned individuals, and the elderly, particularly those aged 60 to 79 years. These findings underscore the need for targeted public health strategies aimed at the prevention and control of myeloid leukemia in this region.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
